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 Hypoxemic Respiratory Failure
 Arterial Po2 of < 60 mm Hg
 Hypercapnic Respiratory Failure 
 Pco2 > 45 mm Hg 
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Hypoxemic respiratory failure 
 Acute  (over hours to days) 
 Chronic  (over weeks to months)
 Oxygen delivery to the tissues 
 cardiac output and oxygen content
Oxygen delivery (DO2 ) 
 rate at which oxygen is transported from the lungs to the microcirculation:
 DO2 (mL/min) = Q x CaO2
 Q is the cardiac output
 Normal DO2 is approximately 1000 mL/min  
Hypoxemic respiratory failure 
 Anemic patient 
 patients with very low cardiac output
 Tissue hypoxia may exist despite a seemingly adequate arterial Po2
Hypoxemic respiratory failure 
 both hypoxemic and hypercarbic respiratory failure may coexist
Hypoventilation
MECHANISMS OF HYPOXEMIA
1. inspired Po2
2. Hypoventilation
3. impaired diffusion
4. ventilation-perfusion (V/Q) mismatch
5. right-to-left shunt 
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Hypoventilation
 PaCO2 & PACO2 
 PAO2 
 diffusion of oxygen from the alveolus to the pulmonary capillary
Net effect is hypoxemia  
As a 
result 
Hypoventilation
A-a gradient is usually normal
A-a oxygen gradient = PAO2 - PaO2
 PaO2 is measured by ABG
 PAO2 is calculated using the alveolar gas equation:
 PAO2  =  (FiO2  x  [Patm - PH2O]) - (PaCO2  ÷ R)
 respiratory quotient = 0.8 at steady state
 relative utilization of carbohydrate, protein, and fat A
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A-a oxygen gradient 
 Air at sea level
 PAo2 = 150 - (Paco2/0.8) 
 P(A-a)O2  should be  10 to 15 mm Hg
Abnormalities that cause pure 
hypoventilation include
 CNS depression
 OHS (Pickwickian) syndrome
 Impaired neural conduction 
 Muscular weakness
 Poor chest wall elasticity
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V/Q mismatch 
 imbalance of blood flow and ventilation
 Hypoxemia can be corrected with O2
 increased A-a gradient 
V/Q mismatch 
V/Q mismatch 
Obstructive lung diseases
Pulmonary vascular diseases
Interstitial diseases
Air-space consolidation
Pneumonia
Pulmonary edema
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Right-to-left shunt 
 when blood passes from the right to the left side of the heart 
 without being oxygenated
 Anatomic shunts 
intracardiac shunts
pulmonary arteriovenous malformations (AVMs)
hepatopulmonary syndrome
 Physiologic shunts 
 atelectasis 
 alveolar filling (eg, pneumonia, ARDS)
Difficult to correct with supplemental oxygen
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Diffusion limitation 
 alveolar and/or interstitial inflammation and fibrosis
 interstitial lung disease
 diffusion limitation usually coexists with V/Q mismatch
 exercise-induced or -exacerbated hypoxemia
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Reduced inspired oxygen tension 
 PiO2 = FiO2 x (Patm - PH2O)
 Reduction of the PiO2 will decrease the PAO2 
 A reduced PiO2 is most commonly associated with high altitude  
Clinical Features and Diagnostic Approach
 Tachypneic
 Tachycardic
 Cyanosis of the lips or tongue 
 Reduced (deoxygenated) hemoglobin is > 5 g/100 mL
Impair oxygen delivery or utilization
Tissue  
hypoxia
Anemic  
hypoxia
Metabolic  
hypoxia
Circulatory
hypoxia
Physical examination 
 CHF
 Consolidation or effusion
 Pneumothorax 
 Arterial hypoxemia 
Hypoventilation
Normal  
A-aPo2 
gradient 
PAO2 = PiO2 – PACO2/R
A-a gradient = PAO2 – PaO2
PaO2 = [ FiO2(PATM-PH2O) – PaCO2/R ] – [ A-a gradient]
Alveolar HypoventilationLow Inspired Oxygen Shunt
V-Q mismatch
Diffusion impairment
Hypoxemic Respiratory Failure
Response well to oxygen therapy
ACUTE RESPIRATORY DISTRESS SYNDROME
(ARDS)
First description of ARDS 
 in 1967 Ashbaugh and colleagues described 12 patients 
ranging in age from 11 to 48 years who presented with 
 respiratory distress
 hypoxemic respiratory failure
 patchy bilateral opacities on chest radiographs
Acute respiratory distress syndrome 
(ARDS) 
 clinical syndrome
 severe dyspnea of rapid onset
 Hypoxemia
 diffuse pulmonary infiltrates 
 respiratory failure
leading 
to 
ARDS
clinical features of ARDS 
Three categories based on the degrees of hypoxemia 






Acute respiratory distress syndrome 
(ARDS) 
 Diffuse lung injury 
 many underlying medical and surgical disorders
 lung injury 
 Direct
 toxic inhalation
 Indirect
 Sepsis  

ARDS
Acute onset
Bilateral opacities  
PAWP <=18 mm Hg 
(absence of clinical evidence of LAH)
Hypoxemia    Po2/Fio2
ARDS
ARDS
 annual incidence 60 cases/100,000 population
 10% of all ICU admissions 
ETIOLOGY
 many medical and surgical illnesses 
 pneumonia and sepsis (~40–60%)
 aspiration of gastric contents
 Trauma
 multiple transfusions
 drug overdose
ETIOLOGY
 many medical and surgical illnesses 
 pneumonia and sepsis (~40–60%)
 aspiration of gastric contents
 Trauma
 Pulmonary contusion
 multiple bone fractures
 chest wall trauma/flail chest 
 head trauma
 near-drowning
 toxic inhalation
 Burns
 multiple transfusions
 drug overdose
Risks of developing ARDS 
> 1 predisposing medical or surgical condition
increased
Lack of Specificity
 Many of the diagnostic criteria for ARDS 
misdiagnosis
non-
specific
Pneumonia
Hydrostatic pulmonary edema
Other Risk Factors
 Older age
 Chronic alcohol abuse 
 Metabolic acidosis
 Pancreatitis
 Severity of critical illness
 Trauma
 APACHE II score ≥16 
 2.5-fold increased risk of developing ARDS 
Diabetes hyperglycemia is known to impair neutrophil function 
ARDS
 Direct injury to the lung
 aspiration pneumonia
 smoke inhalation
 near-drowning
 systemic injury
 Trauma
 Surgery
 Sepsis
 Burns
 Long bone fractures
 Pancreatitis
 Uremia
 transfusion therapy
 Shock 
 drug intoxication
 cardiopulmonary bypass 

Cigarette smoke
active or passive exposure to cigarette smoke
development of ARDS after trauma 
Overview of Pathophysiology in ARDS 
 edema fluid that fills the alveoli is exudative 
 alveolar-capillary barrier exhibits increased permeability
 leakage of protein-rich fluid into the air spaces
 respiratory system compliance 
 Right -to-left shunting 
 profound hypoxemia
 PaCO2 is generally within the normal range
 Dead space ventilation &      minute ventilation 
Time course for the development 
and resolution of ARDS
Pathology
 Exudative  phase  5 -7 days
 Proliferative  phase Days 7-21
 Fibrotic  phase > 21 days
 Recovery phase > 7-21 days
Pathology
Exudative  phase  5 -7 days
 Proliferative  phase Days 7-21
 Fibrotic  phase > 21 days
 Recovery phase > 7-21 days
Exudative phase
 DAD type I pneumocytes (alveolar epithelial cells) 
 Increased permeability 
 Influx of protein rich fluid into alveoli
 enhanced cytokine production
 IL1, IL 8, TNF-α ,LT B4 
 recruitment of leukocytes (especially neutrophils)
 dysfunctional pulmonary surfactant
 vascular obliteration by microthrombi
 fibrocellular proliferation 
Exudative phase of ARDS

If no ARDS risk factor is present
 some objective evaluation is required (e.g., echocardiography) 
 to exclude a cardiac etiology for hydrostatic edema
Exudative Phase
 First 7 days of illness after exposure 
 12–36 hours after the initial insult 
 Dyspnea
 Rapid shallow breathing 
 Inability to get enough air 
 Tachypnea
 Increased work of breathing 
 Respiratory fatigue 
 Respiratory failure
Differential diagnosis of ARDS
 cardiogenic pulmonary edema
 bilateral pneumonia
 alveolar hemorrhage
 acute interstitial lung diseases (AIP)
 acute immunologic injury (HP)
 toxin injury (radiation pneumonitis)
 neurogenic pulmonary edema 
ARDS
Pathology
 Exudative  phase  5 -7 days
 Proliferative  phase Days 7-21
 Fibrotic  phase > 21 days
 Recovery phase > 7-21 days
Proliferative phase 
 Most patients recover rapidly 
 many patients still experience 
 Dyspnea
 Tachypnea 
 Hypoxemia
 Some patients develop progressive lung injury 
 early changes of pulmonary fibrosis
 Shift from neutrophil- to lymphocyte-predominant 
 type II pneumocytes proliferate
Pathology
 Exudative  phase  5 -7 days
 Proliferative  phase Days 7-21
 Fibrotic  phase > 21 days
 Recovery phase > 7-21 days 
Fibrotic phase 3–4 weeks after
 loss of alveolar structure integrity
 pulmonary fibrosis 
 in a subset of patients with persistent > 3 weeks ARDS 
Fibrotic Phase
 Interstitial fibrosis
 long-term support on MV and/or supplemental oxygen. 
 emphysema-like changes, with large bullae 
 Marked disruption of acinar architecture 
 progressive vascular occlusion and pulmonary hypertension 
 Intimal fibroproliferation in the pulmonary microcirculation 
 Pneumothorax 
 Lung compliance
 Pulmonary dead space

ARDS
Clinical presentation of an ARDS patient
 hypoxia
 cyanosis
 tachypnea
 tachycardia
 respiratory alkalosis
 respiratory acidosis
 *** this is usually a diagnosis of exclusion
 rule out a couple of things like pneumonia, HF exacerbation 
Clinical presentation 
 Dyspnea 
 Cyanosis  
 Tachypnea
 Tachycardia
 Diaphoresis 
 Diffuse crackles 
Ventilator-Induced Lung Injury
 mechanical ventilation for ARDS may be lifesaving
 excessive airway pressure could lead to barotrauma 
 Pneumothorax
 pneumomediastinum
 subcutaneous emphysema,
Mechanical ventilation can induce pulmonary edema 
by causing increases in both epithelial and endothelial permeability 
Ventilator-Induced Lung Injury
 Barotrauma 
 A major mechanism causing VILI is overdistention of lung units
 Volutrauma
 Atelectrauma PEEP should be helpful in minimizing this injury
 heterogeneous nature of the pulmonary parenchymal injury
 Biotrauma underlying complex cellular and molecular response
 high tidal volumes 
 zero PEEP 
Elevation in cytokine levels
ARDS
ventilator-induced "volutrauma”
pressure-volume curve of the lung
Post mortem 
specimen from a 
patient with ARDS
CXRay
 Alveolar and interstitial opacities 
 Three-quarters of the lung fields
 Cardiogenic pulmonary edema
ARDS
ARDS
Differential diagnosis of ARDS
 Cardiogenic pulmonary edema
 Diffuse pneumonia
 Alveolar hemorrhage
 Acute interstitial lung diseases 
 Acute immunologic injury        
 hypersensitivity pneumonitis 
 Toxin injury                                                
 radiation pneumonitis
 Neurogenic pulmonary edema

Management of ARDS
 Low  tidal volumes (≤6 mL/kg) 
 Positive  endexpiratory pressure (PEEP)
 Adequate  oxygenation with the lowest FIO2
RECommEndATIonS foR ARdS THERAPIES
Recommendation A
Recommended Therapy 
Low 
tidal 
volume
Recommendation B
Recommended Therapy 
High-PEEP
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Recommendation B
Recommended Therapy 
High-PEEP
ECMO
Prone 
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Recommendation C
recommended only as 
alternative therapy
Inhaled 
epoprosteol
inhaled NO
Recruitment 
maneuvers
Recommendation D
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icoid 
treatment  
High-
frequency 
ventilation
Surfactant 
replacement
Recommendation D
Not Recommended 
NSAIDs
ketoconazole
PGE1
TREATMENT
GENERAL PRINCIPLES
 care of critically ill patients 
1. recognition and treatment of underlying disorders
 (e.g., pneumonia, sepsis, aspiration, trauma); 
2. minimization of unnecessary procedures 
3. “bundled care” approaches 
 Prophylaxis against VTE, GIB, aspiration, excessive sedation 
 prolonged MV, and CV catheter infections; 
4. Nosocomial infections
5. Adequate nutrition  
MANAGEMENT OF MECHANICAL VENTILATION
 Minimizing Ventilator-Induced Lung Injury 
 Minimizing Atelectrauma by Prevention of Alveolar Collapse
 Prone Positioning
 Recruitment maneuvers
 Alternate modes of mechanical ventilation
 Lung-replacement therapy with ECMO 
Minimizing Atelectrauma by 
Prevention of Alveolar Collapse 
 alveolar and interstitial fluid 
 Loss of surfactant 
 reduction of lung compliance.
Minimizing Atelectrauma by 
Prevention of Alveolar Collapse 
 significant alveolar collapse can occur at end-expiration
 Impairment of oxygenation
 positive end-expiratory pressure (PEEP) 
 minimize Fio2 (inspired O2 percentage) 
 provide adequate Pao2 
 without causing alveolar overdistention.
“best PEEP” 
 lower inflection point 
 esophageal pressures to estimate transpulmonary pressure 
 Alveolar recruitment
 Minimizes alveolar overdistention
 hemodynamic instability
 adequate Pao2 while minimizing Fio2
“best PEEP” 
Prone Positioning 
 MV in the prone position 
 improved arterial oxygenation without a mortality benefit
 significant reduction in 28-day mortality (32.8 to 16%) 
 requires a critical-care team 
 accidental endotracheal extubation
 loss of central venous catheters 
 orthopedic injury 
FLUID MANAGEMENT
ARDS
 Increased pulmonary vascular permeability
 impaired vascular integrity
 increasing left atrial pressure
 reduce left atrial filling pressures with fluid restriction and diuretics 
 important aspect of ARDS management
 hypotension and hypoperfusion of critical organs (kidneys) 
aggressive 
attempts to 
NEUROMUSCULAR BLOCKADE
In severe ARDS
 sedation alone 
 early neuromuscular blockade (with cisatracurium besylate) for 48 h, 
 increased survival and ventilator-free days
 without increasing ICU-acquired paresis
GLUCOCORTICOIDS
 Current evidence does not support the routine use 
OTHER THERAPIES
proved disappointing
 Surfactant replacement 
 Pulmonary vasodilators 
 inhaled nitric oxide 
 inhaled epoprostenol sodium 
 transiently improve oxygenation 
 not been shown to improve survival or decrease time on MV  
RECOMMENDATIONS
■PROGNOSIS
 hospital mortality estimates for ARDS 
 34.9% for mild ARDS
 40.3% for moderate ARDS
 46.1% with severe ARDS
 mortality in ARDS is largely attributable to nonpulmonary causes  
 sepsis and nonpulmonary organ failure >80% of deaths
■PROGNOSIS
 The major risk factors for ARDS mortality are nonpulmonary
 Advanced age > 75 years 
 mortality risk (~60%) than those < 45 (~20%) 
 patients >60 years of age with ARDS and sepsis 
 threefold higher mortality risk than those < 60
■PROGNOSIS
Other risk factors 
 preexisting organ dysfunction 
 Chronic liver disease
 Cirrhosis
 Chronic alcohol abuse
 Chronic immunosuppression 
 Direct lung injury 
 Pneumonia
 pulmonary contusion 
 Aspiration
twice as likely to die 
■PROGNOSIS
Other risk factors 
 surgical and trauma patients with ARDS  
 without direct lung injury
 higher survival rate than other ARDS patients
ARDS
 Increasing severity of ARDS
 predicts increased mortality
Berlin
definition
predicting ARDS mortality 
1. Level of PEEP (≥10 cm H2O)
2. Respiratory system compliance (≤ 40 mL/cm H2O)
3. Extent of alveolar infiltrates on chest radiography
4. Corrected expired volume per minute (≥10 L/min) 
 (as a surrogate measure of dead space).
ARDS 
do not usually die of refractory hypoxemia
 most patients with fatal ARDS die of 
 sepsis and multiorgan failure
Functional Recovery in ARDS 
Survivors 
 prolonged respiratory failure 
 mechanical ventilation for survival
 maximal lung function within 6 months
 One year after endotracheal extubation
 >1/3 of ARDS survivors have normal PFT and DLCO
 only mild abnormalities in pulmonary function
 Unlike mortality risk recovery of lung function 
 extent of lung injury in early ARDS
Less recovery of pulmonary function
 Low static respiratory compliance 
 high levels of required PEEP
 longer durations of MV
 high lung injury scores
 Psychological problems 
 Depression  
 Posttraumatic stress disorder 
Therapy
Supportive Care
 treat the underlying cause
 antibiotics 
 surgical débridement and drainage
 sepsis of unknown origin, both the lung and the abdomen 
 prevention of complications 
 nutrition, ventilation
 prophylaxis against gastrointestinal stress ulceration 
 prophylaxis against deep venous thrombosis 
Complications
 ventilator-associated pneumonia 30% to 65% 
 > 5 to 7 days after the onset of MV
 nonfermenting gram-negative rods
 methicillin-resistant Staphylococcus aureus
 Enterobacteriaceae
 barotrauma 10% or less
 Pneumothorax 
 Pneumomediastinum
 Subcutaneous emphysema
long-term complications in survivors 
Neuromuscular  
Psychosocial 

